QQQ   283.62 (-1.40%)
AAPL   144.80 (-1.25%)
MSFT   246.79 (-1.36%)
META   115.58 (-5.60%)
GOOGL   97.23 (-2.26%)
AMZN   89.50 (-1.66%)
TSLA   179.47 (-1.63%)
NVDA   161.46 (-2.79%)
NIO   13.24 (+3.44%)
BABA   91.53 (+1.12%)
AMD   71.42 (-2.99%)
T   19.01 (+1.39%)
MU   54.49 (+0.83%)
CGC   3.76 (-12.96%)
F   13.24 (-1.05%)
GE   85.27 (+0.72%)
DIS   93.87 (-2.15%)
AMC   7.03 (-5.64%)
PYPL   72.67 (-1.29%)
PFE   49.83 (-1.77%)
NFLX   306.70 (-1.88%)
QQQ   283.62 (-1.40%)
AAPL   144.80 (-1.25%)
MSFT   246.79 (-1.36%)
META   115.58 (-5.60%)
GOOGL   97.23 (-2.26%)
AMZN   89.50 (-1.66%)
TSLA   179.47 (-1.63%)
NVDA   161.46 (-2.79%)
NIO   13.24 (+3.44%)
BABA   91.53 (+1.12%)
AMD   71.42 (-2.99%)
T   19.01 (+1.39%)
MU   54.49 (+0.83%)
CGC   3.76 (-12.96%)
F   13.24 (-1.05%)
GE   85.27 (+0.72%)
DIS   93.87 (-2.15%)
AMC   7.03 (-5.64%)
PYPL   72.67 (-1.29%)
PFE   49.83 (-1.77%)
NFLX   306.70 (-1.88%)
QQQ   283.62 (-1.40%)
AAPL   144.80 (-1.25%)
MSFT   246.79 (-1.36%)
META   115.58 (-5.60%)
GOOGL   97.23 (-2.26%)
AMZN   89.50 (-1.66%)
TSLA   179.47 (-1.63%)
NVDA   161.46 (-2.79%)
NIO   13.24 (+3.44%)
BABA   91.53 (+1.12%)
AMD   71.42 (-2.99%)
T   19.01 (+1.39%)
MU   54.49 (+0.83%)
CGC   3.76 (-12.96%)
F   13.24 (-1.05%)
GE   85.27 (+0.72%)
DIS   93.87 (-2.15%)
AMC   7.03 (-5.64%)
PYPL   72.67 (-1.29%)
PFE   49.83 (-1.77%)
NFLX   306.70 (-1.88%)
QQQ   283.62 (-1.40%)
AAPL   144.80 (-1.25%)
MSFT   246.79 (-1.36%)
META   115.58 (-5.60%)
GOOGL   97.23 (-2.26%)
AMZN   89.50 (-1.66%)
TSLA   179.47 (-1.63%)
NVDA   161.46 (-2.79%)
NIO   13.24 (+3.44%)
BABA   91.53 (+1.12%)
AMD   71.42 (-2.99%)
T   19.01 (+1.39%)
MU   54.49 (+0.83%)
CGC   3.76 (-12.96%)
F   13.24 (-1.05%)
GE   85.27 (+0.72%)
DIS   93.87 (-2.15%)
AMC   7.03 (-5.64%)
PYPL   72.67 (-1.29%)
PFE   49.83 (-1.77%)
NFLX   306.70 (-1.88%)
NASDAQ:MREO

Mereo BioPharma Group - MREO Stock Forecast, Price & News

$0.82
-0.01 (-1.25%)
(As of 12/6/2022 09:48 AM ET)
Add
Compare
Today's Range
$0.82
$0.82
50-Day Range
$0.71
$1.01
52-Week Range
$0.30
$1.86
Volume
82 shs
Average Volume
449,419 shs
Market Capitalization
$102.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.25

Mereo BioPharma Group MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
538.7% Upside
$5.25 Price Target
Short Interest
Healthy
4.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.41) to ($0.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

737th out of 1,023 stocks

Pharmaceutical Preparations Industry

356th out of 501 stocks

MREO stock logo

About Mereo BioPharma Group (NASDAQ:MREO) Stock

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

Receive MREO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mereo BioPharma Group and its competitors with MarketBeat's FREE daily newsletter.

MREO Stock News Headlines

See More Headlines
Receive MREO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mereo BioPharma Group and its competitors with MarketBeat's FREE daily newsletter.

MREO Company Calendar

Today
12/06/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MREO
Fax
N/A
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.25
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+538.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$50.14 million
Cash Flow
$0.15 per share
Book Value
$1.03 per share

Miscellaneous

Free Float
N/A
Market Cap
$102.74 million
Optionable
Not Optionable
Beta
0.86

Key Executives

  • Dr. Denise Scots-Knight Ph.D. (Age 63)
    Co-Founder, CEO & Exec. Director
    Comp: $833.03k
  • Mr. Charles Sermon (Age 53)
    Co-Founder, Gen. Counsel & Company Sec.
  • Dr. Alastair MacKinnon M.D. (Age 52)
    MBBS, Co-Founder and Chief of Portfolio & Pipeline Strategy
  • Dr. John P. Richard M.B.A. (Age 65)
    MBA, Co-Founder & Chief Bus. Officer
  • Ms. Christine Fox CPA (Age 41)
    Chief Financial Officer
  • Dr. John A. Lewicki Ph.D. (Age 70)
    Chief Scientific Officer
  • Dr. Jackie Parkin
    Therapy Area Head of Respiratory Endocrinology
  • Ms. Alexandra Hughes-Wilson (Age 51)
    Chief of Patient Access & Commercial Planning
  • Dr. Suba Krishnan
    Sr. VP of Clinical Devel.
  • Dr. Fiona Bor
    Head of Intellectual Property













MREO Stock - Frequently Asked Questions

Should I buy or sell Mereo BioPharma Group stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mereo BioPharma Group in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MREO shares.
View MREO analyst ratings
or view top-rated stocks.

What is Mereo BioPharma Group's stock price forecast for 2023?

4 equities research analysts have issued 12-month price objectives for Mereo BioPharma Group's stock. Their MREO share price forecasts range from $4.00 to $8.00. On average, they expect the company's stock price to reach $5.25 in the next twelve months. This suggests a possible upside of 538.7% from the stock's current price.
View analysts price targets for MREO
or view top-rated stocks among Wall Street analysts.

How have MREO shares performed in 2022?

Mereo BioPharma Group's stock was trading at $1.60 at the beginning of the year. Since then, MREO stock has decreased by 48.6% and is now trading at $0.8220.
View the best growth stocks for 2022 here
.

What other stocks do shareholders of Mereo BioPharma Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mereo BioPharma Group investors own include VBI Vaccines (VBIV), Pfizer (PFE), Otonomy (OTIC), OpGen (OPGN), OPKO Health (OPK), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Vaxart (VXRT), Aduro Biotech (ADRO) and Affimed (afmd).

When did Mereo BioPharma Group IPO?

(MREO) raised $49 million in an IPO on the week of April 23rd 2018. The company issued 2,800,000 shares at a price of $17.62 per share. Cowen, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Cantor Fitzgerald Europe were co-managers.

What is Mereo BioPharma Group's stock symbol?

Mereo BioPharma Group trades on the NASDAQ under the ticker symbol "MREO."

Who are Mereo BioPharma Group's major shareholders?

Mereo BioPharma Group's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Rubric Capital Management LP (8.29%), Point72 Asset Management L.P. (7.86%), Clearline Capital LP (3.17%), Renaissance Technologies LLC (0.99%), BlackRock Inc. (0.53%) and Monaco Asset Management SAM (0.16%).

How do I buy shares of Mereo BioPharma Group?

Shares of MREO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mereo BioPharma Group's stock price today?

One share of MREO stock can currently be purchased for approximately $0.82.

How much money does Mereo BioPharma Group make?

Mereo BioPharma Group (NASDAQ:MREO) has a market capitalization of $102.74 million and generates $50.14 million in revenue each year.

How can I contact Mereo BioPharma Group?

Mereo BioPharma Group's mailing address is ONE CAVENDISH PLACE FOURTH FLOOR, LONDON X0, W1G0QF. The official website for the company is www.mereobiopharma.com. The company can be reached via phone at 44-33-3023-7300 or via email at investors@mereobiopharma.com.

This page (NASDAQ:MREO) was last updated on 12/6/2022 by MarketBeat.com Staff